Tazemetostat
- Generic Name
- Tazemetostat
- Brand Names
- Tazverik
- Drug Type
- Small Molecule
- Chemical Formula
- C34H44N4O4
- CAS Number
- 1403254-99-8
- Unique Ingredient Identifier
- Q40W93WPE1
- Background
Tazemetostat is a methyltransferase inhibitor used to treat metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. Tazemetostat was first named in literature as EPZ-6438.
Tazemetaostat was granted FDA approval on 23 January 2020.
- Indication
Tazemetostat is indicated to treat adult and pediatric patients 16 years and older with metastatic or locally advanced epithelioid sarcoma that is not eligible for complete resection. It is also indicated to treat adult patients with relapsed or refractory follicular lymphoma whose tumors are positive for an IZH2 mutation and who have received at least 2 pri...
- Associated Conditions
- Locally Advanced Epithelioid Sarcoma, Metastatic Epithelioid Sarcoma, Refractory Follicular Lymphoma, Relapsed Follicular Lymphoma
- Associated Therapies
- -
A Study of Tazemetostat (Tazverik) Before Prostatectomy in Men With Prostate Cancer
- First Posted Date
- 2022-10-05
- Last Posted Date
- 2023-09-22
- Lead Sponsor
- Edwin Posadas, MD
- Registration Number
- NCT05567679
- Locations
- 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
A Study of Tazemetostat With Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2022-09-23
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Vaishalee Kenkre
- Target Recruit Count
- 42
- Registration Number
- NCT05551936
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸University of Illinois Cancer Center, Chicago, Illinois, United States
🇺🇸Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Tazemetostat for the Treatment of Relapsed/Refractory Follicular Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2022-07-21
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Hutchmed
- Target Recruit Count
- 42
- Registration Number
- NCT05467943
- Locations
- 🇨🇳
Shanghai Cancer Center, Shanghai, Shanghai, China
Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors
- Conditions
- Interventions
- First Posted Date
- 2022-06-07
- Last Posted Date
- 2023-08-22
- Lead Sponsor
- Susan Chi, MD
- Target Recruit Count
- 49
- Registration Number
- NCT05407441
- Locations
- 🇺🇸
Boston Children's Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2022-05-12
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 220
- Registration Number
- NCT05372354
- Locations
- 🇨🇦
University Health Network UHN - Princess Margaret Hospital PMH, Toronto, Ontario, Canada
🇺🇸John Theurer Cancer Center at Hackensack UMC, Hackensack, New Jersey, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
A Study of Tazemetostat on Safety in Participants With Relapsed or Refractory Follicular Lymphoma With Enhancer of Zeste Homolog 2 (EZH2) Gene Mutation in Japan
- First Posted Date
- 2022-02-08
- Last Posted Date
- 2023-12-18
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 145
- Registration Number
- NCT05228158
- Locations
- 🇯🇵
Eisai Trial Site 149, Shinagawa-Ku, Tokyo, Japan
🇯🇵Eisai Trial Site 77, Bunkyo-ku, Tokyo, Japan
🇯🇵Eisai Trial Site 120, Komae-shi, Tokyo, Japan
A Study of Tazemetostat in Combination With Various Treatments in Participants With Blood Cancer.
- Conditions
- Interventions
- First Posted Date
- 2022-01-25
- Last Posted Date
- 2023-08-15
- Lead Sponsor
- Epizyme, Inc.
- Registration Number
- NCT05205252
- Locations
- 🇺🇸
Central Care Cancer Center, Bolivar, Missouri, United States
🇺🇸California Cancer Associates For Research And Excellence, cCARE, Santa Fe, California, United States
🇺🇸Astera Cancer Center, East Brunswick, New Jersey, United States
Tazemetostat in Combination With Umbralisib and Ublituximab for the Treatment Relapsed or Refractory Follicular Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2021-12-09
- Last Posted Date
- 2023-05-31
- Lead Sponsor
- City of Hope Medical Center
- Registration Number
- NCT05152459
Induction Chemotherapy and Tazemetostat for Locally Advanced SMARCB1-deficient Sinonasal Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2021-12-09
- Last Posted Date
- 2023-02-28
- Lead Sponsor
- Dr. Victor H.F. Lee
- Target Recruit Count
- 30
- Registration Number
- NCT05151588
Phase II Study of Tazemetostat in Solid Tumors Harboring an ARID1A Mutation
- First Posted Date
- 2021-08-26
- Last Posted Date
- 2024-07-22
- Lead Sponsor
- Prisma Health-Upstate
- Target Recruit Count
- 40
- Registration Number
- NCT05023655
- Locations
- 🇺🇸
Prisma Health Cancer Institute, Greenville, South Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.